An implantable leadless pacemaker (iLP) for a human or animal heart is provided that includes a housing, at least two electrode poles for picking up electrical potentials and/or delivering electrical stimulation, a stimulation control unit in connection with the electrode poles, a sensing unit that is in connection with at least one electrode pole, a signal processing unit in connection with the sensing unit, a signal evaluation unit in connection with the signal processing unit and/or the sensing unit, and an energy source. The sensing unit is configured to sense a first signal associated with an activity of the first heart chamber, and the stimulation control unit is configured to deliver electrical stimulation in the first heart chamber via the at least two electrode poles. The sensing unit is configured to sense a second signal associated with an activity of a second heart chamber.

Systems and methods for controlling blood pressure via electrical stimulation of the heart are disclosed. Embodiments may include at least two different stimulation patterns, each configured to reduce blood pressure to a different degree, and may alternate between stimulation patterns based on the need of a patient, for example, alternating between day and night or between periods of strenuous and light activity. Some embodiments may take advantage of a slow baroreflex response that occurs after treatment is stopped, suspending treatment for extended periods, and then resuming treatment before blood pressure levels reach pretreatment values. Embodiments may control blood pressure by controlling atrial pressure and atrial stretch.

The control module of a first pacemaker included in an implantable medical device system including the first pacemaker and a second pacemaker is configured to set a pacing escape interval in response to a far field pacing pulse sensed by the first pacemaker. The far field pacing pulse is a pacing pulse delivered by the second pacemaker. The pacing escape interval is allowed to continue without restarting the in response to a far field intrinsic event sensed by the first pacemaker during the pacing escape interval. The first pacemaker delivers a cardiac pacing pulse to the heart upon expiration of the pacing escape interval.

Certain embodiments of the present technology described herein relate to detecting atrial oversensing, characterizing atrial oversensing, determining when atrial oversensing is likely to occur, and or reducing the chance of atrial oversensing occurring. Some such embodiments characterize and/or avoid atrial oversensing.

A method and implantable medical device system for delivering a cardiac pacing therapy that includes suspending delivery of the LV cardiac pacing therapy and sensing far-field cardiac signals via one or more far-field sensing vectors formed between a plurality of electrodes positioned on a single-pass coronary sinus lead. Far-field signal features are determined in response to the sensed far-field cardiac signals, a first offset interval and a second offset interval are determined in response to the determined far-field signal features, and an AV delay of the LV cardiac pacing therapy is adjusted in response to the determined first offset interval and second offset interval. Delivery of the LV cardiac pacing therapy having the adjusted AV delay is subsequently resumed.

A method and implantable medical device system for delivering a left ventricular (LV) cardiac pacing therapy via a single-pass coronary sinus lead and sensing far-field cardiac signals via one or more far-field sensing vectors formed between the plurality of electrodes. Beat morphologies corresponding to the far-field cardiac signals are determined, and a beat morphology match between each of the far-field beat morphologies and an intrinsic beat morphology template is determined so that one of loss of LV capture, pseudo fusion and loss of synchrony is determined in response to the determined beat morphology match. One of a loss of capture adjustment, a pseudo fusion adjustment, and a resynchronization adjustment is performed in response to the determined one of loss of LV capture, pseudo fusion and loss of synchrony in response to the determined beat morphology match to generate an adjusted LV cardiac pacing therapy.

Brugada syndrome and related forms of ion channelopathies, including ventricular asynchrony of contraction, originate in the region near the His bundle or para-Hisian regions of the heart. Manifestations of Brugada syndrome can be corrected by delivering endocardial electrical stimulation coincident to the activation wave front propagated from the atrioventricular (AV) node. By performing the start of the activation of the HIS bundle or para-Hisian region early enough, electrical stimulation can be delivered fast enough to compensate for the conduction problems that start in those region, such that the activation wave front, as stimulated, transitions from the AV node to the His bundle in a normal, albeit electrically-supplemented, fashion. This stimulation not only helps resolve the conditions that trigger Brugada syndrome, but also resolves the asynchrony of the contraction of the heart.

A ventricular pacemaker is configured to determine a ventricular rate interval by determining at least one ventricular event interval between two consecutive ventricular events and determine a rate smoothing ventricular pacing interval based on the ventricular rate interval. The pacemaker is further configured to detect an atrial event from a sensor signal and deliver a ventricular pacing pulse in response to detecting the atrial event from the sensor signal. The pacemaker may start the rate smoothing ventricular pacing interval to schedule a next pacing pulse to be delivered upon expiration of the rate smoothing ventricular pacing interval.

A method of employing an implantable medical device to detect pacemaker mediated tachycardia (PMT) and adjusting a parameter (e.g. PVARP) in response to confirmation of the PMT. The method comprises, with a processor located in the implantable medical device, (1) measuring a first Vp-As (VA1), (2) lengthening SAV by 50 ms for 1 beat in response to measuring VA1, (3) measuring a second Vp-As (VA2), (4) returning to a normal SAV, (5) measuring a third Vp-As (VA3), (6) determining whether VA1=VA2 and VA1=VA3, (7) in response to determining whether VA1=VA2 and VA1=VA3, confirming presence of PMT, and (8) in response to confirming presence of PMT, PVARP is extended.

An intracardiac ventricular pacemaker having a motion sensor is configured to produce a motion signal including an atrial systolic event and a ventricular diastolic event indicating a passive ventricular filling phase, set a detection threshold to a first amplitude during an expected time interval of the ventricular diastolic event and to a second amplitude lower than the first amplitude after an expected time interval of the ventricular diastolic event. The pacemaker is configured to detect the atrial systolic event in response to the motion signal crossing the detection threshold and set an atrioventricular pacing interval in response to detecting the atrial systolic event.